文献速递慢性肾脏病

心脏生物标志物与CKD患者死亡风险:CRIC研究

Cardiac Biomarkers and Risk of Mortality in CKD (the CRIC Study).
PubMed 文献 · Kidney Int Rep · 2020-09-10

在3664例CKD成人中,基线NT-proBNP、hsTnT、GDF-15和sST-2升高均与全因及心血管死亡风险增加独立相关;842例亚组中,2年内NT-proBNP和sST2下降与全因死亡风险降低相关。

要点

  • 基线NT-proBNP、hsTnT、GDF-15、sST-2升高均与CKD患者全因死亡风险增加独立相关。
  • 4种标志物基线升高亦与心血管死亡风险增加相关。
  • 2年内NT-proBNP或sST2下降与全因死亡风险降低相关。

核心结论

  • 在CKD患者中,NT-proBNP、hsTnT、GDF-15和sST-2升高与全因及心血管死亡风险增加独立相关。
  • NT-proBNP和sST2随时间下降与全因死亡风险降低相关。

研究设计与样本

  • 慢性肾功能不全队列研究(CRIC)中3664例CKD成人的队列研究。
  • 亚组842例参与者分析2年内生物标志物变化与全因死亡风险。
  • 采用Cox比例风险回归模型,调整人口学、肾功能、心血管危险因素和用药。

主要发现

  • 基线NT-proBNP升高与全因死亡风险增加相关(HR=1.92,95%CI 1.73-2.12)。
  • 基线hsTnT升高与全因死亡风险增加相关(HR=1.62,95%CI 1.48-1.78)。
  • 基线GDF-15升高与全因死亡风险增加相关(HR=1.61,95%CI 1.46-1.78)。
  • 基线sST-2升高与全因死亡风险增加相关(HR=1.26,95%CI 1.16-1.37)。
  • 4种标志物基线升高均与心血管死亡风险增加相关;NT-proBNP下降(HR=0.55,95%CI 0.36-0.86)和sST2下降(HR=0.55,95%CI 0.36-0.86)与全因死亡风险降低相关。

临床怎么用

  • 在CKD患者中可检测NT-proBNP、hsTnT、GDF-15和sST-2以辅助评估全因及心血管死亡风险。
  • 动态监测NT-proBNP和sST2的变化可能有助于进一步风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Cardiovascular disease (CVD) is the leading cause of mortality among individuals with chronic kidney disease (CKD). Cardiac biomarkers of myocardial distention, injury, and inflammation may signal unique pathways underlying CVD in CKD. In this analysis, we studied the association of baseline levels and changes in 4 traditional and novel cardiac biomarkers with risk of all-cause, CV, and non-CV mortality in a large cohort of patients with CKD. METHODS: Among 3664 adults with CKD enrolled in the Chronic Renal Insufficiency Cohort Study, we conducted a cohort study to examine the associations of baseline levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), cardiac high-sensitivity troponin T (hsTnT), growth differentiation factor-15 (GDF-15), and soluble ST-2 (sST-2) with risks of all-cause and cardiovascular (CV) mortality. Among a subcohort of 842 participants, we further examined the associations between change in biomarker levels over 2 years with risk of all-cause mortality. We used Cox proportional hazards regression models and adjusted for demographics, kidney function measures, cardiovascular risk factors, and medication use. RESULTS: After adjustment, elevated baseline levels of each cardiac biomarker were associated with increased risk of all-cause mortality: NT-proBNP (hazard ratio [HR] = 1.92, 95% confidence interval [CI] = 1.73-2.12); hsTnT (HR = 1.62, 95% CI = 1.48, 1.78]); GDF-15 (HR = 1.61, 95% CI = 1.46-1.78]); and sST-2 (HR = 1.26, CI = 1.16-1.37). Higher baseline levels of all 4 cardiac biomarkers were also associated with increased risk of CV. Declines in NT-proBNP (adjusted HR = 0.55, 95% CI = 0.36-0.86) and sST2 (HR = 0.55, 95% CI = 0.36-0.86]) over 2 years were associated with lower risk of all-cause mortality. CONCLUSION: In a large cohort of CKD participants, elevations of NT-proBNP, hsTnT, GDF-15, and sST-2 were independently associated with greater risks of all-cause and CV mortality.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Wang K, Zelnick LR, Anderson A, et al. Cardiac Biomarkers and Risk of Mortality in CKD (the CRIC Study). Kidney Int Rep. 2020. PMID: 33163721. doi:10.1016/j.ekir.2020.08.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。